Immunocore Hldgs (NASDAQ:IMCR) reported second-quarter financial results on Thursday. The transcript

IMCR achieves target enrollment in the phase III TEBE-AM study investigating Kimmtrak in previously

Immunocore Holdings plc (IMCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference T

Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-

Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK

Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & RADNOR, PA & GAITHERS

Bank of America Corp DE trimmed its position in Immunocore Holdings PLC Sponsored ADR (NASDAQ: IMCR)

Strong demand for Kimmtrak is fueling Immunocore's growth, while potential label expansion and late-

JP Morgan analyst Jessica Fye reinstates Immunocore Holdings (NASDAQ:IMCR) with a Overweight and

Immunocore's 3-month gain reflects Kimmtrak growth and pipeline progress, but valuation and mixed si

Immunocore's Kimmtrak growth and late-stage catalysts strengthen its case, but a premium valuation a

Immunocore's Q2 revenue beat reflects strong Kimmtrak demand, but an EPS miss and distributor stocki

IMCR incurs wider-than-expected Q2 loss. However, revenues beat as sole drug Kimmtrak sales rise 18.

The average of price targets set by Wall Street analysts indicates a potential upside of 77.9% in Im

Immunocore Holdings plc (IMCR) Q2 2026 Earnings Call Transcript

Immunocore NASDAQ: IMCR reported continued growth for KIMMTRAK in the second quarter and first half

Immunocore Hldgs (NASDAQ:IMCR) reported quarterly losses of $(0.02) per share which missed the analy

Immunocore reports second quarter financial results and provides a business update KIMMTRAK ® (teben

Mizuho analyst Graig Suvannavejh maintains Immunocore Holdings (NASDAQ:IMCR) with a Neutral and r

Immunocore to report second quarter 2026 financial results and host call on August 6, 2026 (OXFORDSH

IMCR's Kimmtrak sales climbed 29% in 2025 on wider adoption, with pivotal 2026 trial results set to

Kimmtrak's sales growth supports IMCR, but premium valuation and reliance on one product keep invest

Kimmtrak anchors IMCR today, but its broader T-cell receptor platform is targeting larger cancer, in

Immunocore has transitioned from a rare-disease oncology company to a self-funded platform company w

IMCR is seeing strong Kimmtrak sales growth and pursuing label expansion studies that could broaden

https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/october-december-2025-new-safety-

Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings a

  On Thursday, 369 companies hit new 52-week lows.

Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterl

Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss a

  During Monday's session, 50 stocks hit new 52-week highs.

Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 176.5% to close at $31.00 on Thursday after

  Companies Reporting Before The Bell • Wix.com (NASDAQ:WIX) is estimated to report earnings for i

U.S. stocks closed mixed on Thursday following the release of weekly jobless claims data. Here is th

    On Friday morning, 155 companies achieved new lows for the year.

  On Monday morning, 207 companies hit new 52-week lows.

Gainers Atlantic American Corporation. (NASDAQ: AAME) shares surged 117.6% to close at $5.20 on F